The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations

Ming-Szu Hung (MD, PhD)\textsuperscript{a,b,c}, Jr-Hau Lung (PhD)\textsuperscript{d}, Yu-Ching Lin (MD, PhD)\textsuperscript{a,b,c}, Yu-Hung Fang (MD)\textsuperscript{a}, Meng-Jer Hsieh (MD)\textsuperscript{e,f}, Ying-Huang Tsai (MD)\textsuperscript{a,f}, Jr-Hau Lung (PhD)\textsuperscript{d}, Yu-Ching Lin (MD, PhD)\textsuperscript{a,b,c}, Yu-Hung Fang (MD)\textsuperscript{a}, Meng-Jer Hsieh (MD)\textsuperscript{e,f}, Ying-Huang Tsai (MD)\textsuperscript{a,f}

Abstract

This study aimed to elucidate the association of the content of mutant epidermal growth factor receptor (EGFR) deoxyribonucleic acid (DNA) with the treatment response to EGFR-tyrosine kinase inhibitor (TKI) and survival in patients with lung cancer.

This retrospective cohort study included 77 lung adenocarcinoma patients with common EGFR mutations from December 2012 to February 2015. The content of mutant EGFR DNA in lung cancer tissues was determined using an Amplification Refractory Mutation System. The association of the amount of mutant DNA with treatment response, the clinical variables, and the progression-free survival (PFS) after EGFR-TKI therapy were evaluated.

Using the amount of mutant EGR DNA above 4.77% as the cut-off value, the sensitivity to predict EGFR-TKI responder is 82.0% and the specificity is 75.0% (area under the curve [AUC]: 0.734, \( P = 0.003 \)). The high content of mutant EGFR DNA is an independent factor associated with the response to EGFR-TKIs (odds ratio: 13.07, 95% confidence interval [CI]: 3.23–52.11, \( P = 0.0003 \)). A significantly longer PFS was observed in the group with the high content of mutant EGFR DNA (26.3 months, 95% CI: 12.2–26.3) compared with the low content of mutant EGFR DNA groups (12.3 months, 95% CI: 5.7–14.8, \( P = 0.0155 \)). A better predictive value of the content of mutant DNA was noted in patients with exon 19 deletions (AUC: 0.892, \( P < 0.0001 \)) than exon 21 L858R mutations (AUC: 0.675, \( P = 0.0856 \)).

Our results show that the content of mutant EGFR DNA is associated with the clinical response to EGFR-TKIs, especially in patients with exon 19 deletions mutation.

Abbreviations: AJCC = American Joint Committee on Cancer, AUC = area under the curve, CR = complete response, DCR = disease control rate, dCt = delta Ct, DNA = deoxyribonucleic acid, EGFR = epidermal growth factor receptor, EGFR-TKI = epidermal growth factor tyrosine kinase inhibitor, NSCLC = nonsmall cell lung cancer, ORR = overall response rate, OS = overall survival, PD = progressive disease, PFS = progression-free survival, PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumors, ROC = receiver operating characteristic, SD = stable disease.

Keywords: EGFR, EGFR-TKI, lung cancer

1. Introduction

The epidermal growth factor receptor (EGFR) pathway is an attractive target for lung cancer therapy, because EGFR signaling pathway plays an important role in the growth, proliferation, and survival of many solid tumors, including nonsmall cell lung cancer (NSCLC).\textsuperscript{[7]} A subgroup of patients with NSCLC having specific mutations in the tyrosine kinase domain of the EGFR gene, which correlates with favorable clinical responsiveness to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, has been noted.\textsuperscript{[2]} All mutations appear to be limited to exons 18, 19, 20, and 21 of the EGFR gene\textsuperscript{[3]} and are most frequently found in patients with lung adenocarcinoma.\textsuperscript{[4]}

EGFR mutations have been found in fewer than 10% of non-Asian patients with NSCLC,\textsuperscript{[5]} and in 30% of East Asians’ patients.\textsuperscript{[6]} Missense mutations in exon 21 (L858R) and in-frame deletions within exon 19 have been shown to be the most frequent EGFR-TKI sensitive mutations (80%) in NSCLC.\textsuperscript{[7]} Both exon 19 deletion and exon 21 missense mutations are common EGFR mutations and have been proved to be associated with a favorable response to first-line treatment with gefitinib\textsuperscript{[8]} as well as other EGFR-TKIs such as erlotinib\textsuperscript{[9]} and afatinib\textsuperscript{[10]} compared with standard chemotherapy in patients with NSCLC. In contrast, NSCLC tumors with wild-type EGFR receptors often
do not respond to EGFR inhibitor therapy and actually are more responsive to traditional chemotherapy.\[8\] As a result, identifying EGFR mutation status before initiation of EGFR-TKI therapy is advocated for patients with NSCLC.\[11\]

Intratumoral heterogeneity, which is due to cancer cells with different genetic alterations in a tumor tissue, could contribute to resistance to anticancer drugs.\[12,13\] Intratumoral heterogeneity of EGFR mutations has been reported to be a potential source of treatment failure and drug resistance to EGFR-TKIs.\[12,13\]

Further studies have also shown that the mutant EGFR content is associated with the treatment response to EGFR-TKIs.\[14\] As a result, we propose that the content of mutant EGFR deoxyribonucleic acid (DNA) could be used in the prediction of the treatment response to EGFR-TKIs in patients with NSCLC.

In this study, we attempted to determine the content of mutant EGFR DNA in lung cancer cells and NSCLC tissues using the Therascreen EGFR RGQ PCR kit (Qiagen, Hilden, Germany). Then, we evaluated the association of the content of mutant EGFR DNA with the treatment response to EGFR-TKI and survival in advanced lung adenocarcinoma patients with common EGFR mutations.

2. Materials and methods

2.1. Patients and study design

This study is a retrospective cohort study. After being approved by the Institution Review Board of Chang Gung Memorial Hospital, we evaluated 77 patients with lung adenocarcinoma in Chang Gung Memorial Hospital, Chiayi Branch diagnosed from December 2012 to February 2015. All patients were treatment-naive at the time of initial diagnosis and were enrolled in our study. The clinical variables of these patients were analyzed. Patients with exon 19 deletions and exon 21 L858R mutations were excluded from our study. The clinical variables of these patients were analyzed. Patients were treated with gefitinib (250 mg/d), erlotinib (150 mg/d), or afatinib (40 mg/d) until the progression of disease. The response of lesions was evaluated by chest computed tomography, brain magnetic resonance imaging, or bone scan according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,\[11,11\] 3 months after the initiation of treatment. EGFR-TKI responders were classified as complete response or partial response (PR) and nonresponders were classified as stable disease (SD) or progressive disease (PD). 3 months after the initiation of EGFR-TKI therapy. Progression-free survival (PFS) refers to the time from the first treatment to PD or death in patients. Overall survival (OS) refers to the time from the diagnosis to the cause of death or patients were censored at last follow-up.

2.2. Cell culture and DNA extraction

Two NSCLC cell lines H1650 (ATCC CRL-5883) and H1975 (ATCC CRL-5908), and human embryonic kidney 293 cell line (HEK293, ATCC CRL-1573), were purchased from American Type Culture Collection (Manassas, VA). The HEK293 cell line has wild-type EGFR and both H1650 and H1975 cell lines have EGFR mutations (heterozygous exon 19 delE746-A750 for H1650, heterozygous exon 21 L858R, and exon 20 T790M for H1975).\[16\] Cells were grown in Roswell Park Memorial Institute growth media supplemented with 10% fetal calf serum, 30 ng/mL EGF, 10U/mL penicillin, and 10 μg/mL streptomycin at 37°C and 5% CO₂.

DNA was extracted from formalin-fixed paraffin embedded tumors using the QIAamp DNA FFPE Tissue Kit and from cell lines using the QIAamp DNA Mini Kit (Qiagen).

2.3. Determination of the percentage of mutant EGFR DNA

After extraction of DNA for cell lines, the mutant EGFR DNA was mixed with wild-type EGFR DNA at different percentages (0.5%, 2.5%, 5%, 10%, 20%, and 50%) in a final concentration of 5 ng/μL. EGFR mutation analysis for the mixed DNA samples was performed using the Therascreen EGFR RGQ PCR kit (Qiagen) according to manufacturer’s manual.\[17\] Delta Ct (ΔCt) is calculated as the difference between the mutation assay Ct and control assay Ct from the same sample. The correlation of ΔCt and the logarithmic values of the percentage of mutant EGFR DNA were then evaluated.

2.4. Statistical analysis

The Pearson χ² test was used to elucidate the differences of categorical variables among different groups. Receiver operating characteristic (ROC) curves and the Youden index were used to determine optimal cut-off values. Survival analysis was performed with a Kaplan–Meier analysis and log-rank test. Multivariate analysis was performed by logistic regression. A value of P < 0.05 was regarded as statistically significant. All statistical tests were analyzed using the computer software MedCalc version 15 (MedCalc Software, Ostend, Belgium).

3. Results

3.1. Patient characteristics

In our study, 77 lung adenocarcinoma patients with common EGFR mutations were enrolled (Table 1). The median age was 67.7 years (41–92 years). Most patients were female gender (n=40, 52%), never-smoker (n=68, 88.3%), and stage IV (n=72, 93.5%) patients. Among those patients, 34 (44.2%) patients were with exon 19 deletions and 43 (55.8%) patients were with exon 21 L858R missense EGFR mutations. Gefitinib (n=45, 58.4%), erlotinib (n=27, 35%), or afatinib (n=5, 6.6%) EGFR-TKIs were used for the first-line therapy in those patients. Three months after EGFR-TKI treatment, tumor response to treatment was evaluated and PR in 61 (79.2%), SD in 8 (10.4%), and PD in 8 (10.4%) patients were observed. The overall response rate to EGFR-TKIs was 79.2% and the disease control rate was 89.6%. The median PFS for all first-line EGFR-TKI patients was 14.8 months (95% confidence interval [CI]: 12.2–26.3 months) and median OS was not reached. Of the 77 samples, 21 (27.3%) were obtained from bronchoscopy biopsy, 31 (40.3%) from transthoracic biopsy, 14 (18.2%) from surgical biopsy, 7 (9.1%) from pleural biopsy, and 4 (5.2%) from pleural effusion cytology. Rebiopsy was performed in 11 patients after progression of the disease and exon 20 T790M mutation was observed in 4 (36.4%) of 11 patients.

3.2. The percentage of mutant EGFR DNA correlates with ΔCt

To evaluate the association of ΔCt and the amount of mutant EGFR DNA, exon 19 deletions, and exon 21 L858R EGFR
mutations were determined by the Therascreen EGFR RGQ PCR kit under different percentages of the mutant EGFR DNA. Linear regression was performed and a significant correlation was observed between the dCt and logarithmic values of the percentage of mutant EGFR DNA in both exon 19 deletions ($R^2 = 0.9754$, $P = 0.0002$, dCt $= -2.743 \log \text{DNA} \% + 5.491$) and exon 21 L858R ($R^2 = 0.9628$, $P = 0.0005$, dCt $= -2.377 \log \text{DNA} \% + 6.332$) mutations (Fig. 1). The content of mutant DNA in tumor samples was then calculated according to equations as previously described. The median content of the mutant EGFR DNA in all lung cancer tissues tested was 9.41% (95% CI: 7.38–15.44). Less than 0.5% of the mutant EGFR DNA was observed in 2 samples (0.12% and 0.27%), and more than 50% of the mutant EGFR DNA was observed in 3 samples (110.0%, 148.5%, and 2440%). All 3 patients with the percentage of the mutant EGFR DNA content more than 50% showed PR after EGFR-TKI therapy.

3.3. The percentage of mutant EGFR DNA correlates with clinical response to EGFR-TKI and survival

The sensitivity of the percentage of mutant EGFR DNA to predict clinical response to EGFR-TKIs was then evaluated. Using the percentage of mutant DNA above 4.77% as the cut-off value, the sensitivity to predict EGFR-TKI responder is 82% and the specificity is 75.0% (area under the curve [AUC]: 0.734, $P = 0.003$) (Fig. 2A). Logistic regression was performed to evaluate the relationship between the response to EGFR-TKIs and variables including age, sex, gender, EGFR mutation status, and mutant EGFR DNA content. The high content of mutant EGFR DNA is an independent factor associated with the response to EGFR-TKIs (odds ratio: 13.07, 95% CI: 3.23–52.11, $P = 0.0003$) (Table 2).

The patients were then grouped into high and low content of the mutant EGFR DNA groups using 4.77% of mutant DNA as the cut-off value. A significantly higher proportion of EGFR-TKI responders was observed in high percentage of mutant DNA group compared with low percentage group (90.9% vs 50%, $P = 0.0001$) (Table 1). A significantly longer PFS was observed in the group with high content of mutant EGFR DNA (26.3 months, 95% CI: 12.2–26.3) compared with the low content of mutant EGFR DNA groups (12.3 months, 95% CI: 5.7–14.8, $P = 0.0155$) (Fig. 2B). There was no significant difference in gender, age, EGFR-TKI use, mutation status, and carcinoembryonic antigen levels between both groups.

The content of mutant EGFR DNA was further evaluated individually in exon 19 deletions and exon 21 L858R mutation patients. A better predictive value of the content of mutant EGFR

---

**Table 1**

| Patients' characteristics and clinical variables. | Total | High DNA % | Low DNA % | $P$ value |
|--------------------------------------------------|-------|------------|-----------|----------|
| Patients                                         | 77    | 55         | 22        |          |
| Gender                                           |       |            |           |          |
| Male                                             | 37 (48%) | 29 (52.7%) | 8 (36.4%) | 0.1971   |
| Female                                           | 40 (52%) | 26 (47.3%) | 14 (63.7%)|          |
| Smoking                                          |       |            |           |          |
| Yes                                              | 9 (11.7%) | 7 (12.7%)  | 2 (9.1%)  | 0.6558   |
| No                                               | 68 (88.3%) | 48 (87.3%) | 20 (90.9%)|          |
| Age, y                                           | 67.7  | 88.0       | 67.0      | 0.7599   |
| TKI                                              |       |            |           |          |
| Erlotinib                                        | 27 (35%) | 21 (38.2%) | 6 (27.3%) | 0.1646   |
| Gefitinib                                        | 45 (58.4%) | 29 (52.7%) | 16 (72.7%)|          |
| Afatinib                                         | 5 (6.6%)  | 5 (9.1%)   | 0         |          |
| Mutations                                        |       |            |           |          |
| Exon 19                                          | 34 (44.2%) | 25 (45.5%) | 9 (40.9%) | 0.7185   |
| Exon 21                                          | 43 (55.8%) | 30 (54.5%) | 13 (59.1%)|          |
| Stage                                            |       |            |           |          |
| I       | 5 (6.5%)  | 4 (7.3%)   | 1 (4.5%)  | 0.6629   |
| II      | 72 (93.5%) | 51 (92.7%) | 21 (95.5%)|          |
| CEA, ng/mL                                       | 91.5  | 95.5       | 81.8      | 0.8878   |
| DNA % (median)                                   | 9.4   | 15.0       | 2.4       | <0.0001* |
| TKI response                                     |       |            |           |          |
| Responder                                        | 61 (79.2%) | 50 (90.9%) | 11 (50%)  | 0.0001*  |
| Nonresponder                                     | 16 (20.8%) | 5 (9.1%)   | 11 (50%)  |          |

CEA = carcinoembryonic antigen, DNA = deoxyribonucleic acid, TKI = tyrosine kinase inhibitor.

* Determined by Mann–Whitney test.

**Figure 1.** The association of the percentage of EGFR mutant DNA and delta Ct determined by the Therascreen EGFR RGQ PCR kit (Qiagen) in lung cancer cells. DNA = deoxyribonucleic acid, EGFR = epidermal growth factor.
DNA was noted in patients with exon 19 deletions (AUC: 0.892, \( P < 0.0001 \)) (Fig. 3A) than exon 21 L858R mutation (AUC: 0.675, \( P = 0.0856 \)) (Fig. 3B). Using the percentage of mutant DNA above 3.93% as the cut-off value, the sensitivity to predict EGFR-TKI responder is 83.33% and the specificity is 100% in patients with exon 19 deletion mutations. In those patients, a significantly longer PFS was observed in high percentage of mutant DNA groups (26.3 months, 95% CI: 26.3–26.3) compared with low percentage mutant DNA groups (14.8 months, 95% CI: 5.4–21.3, \( P = 0.023 \)) (Fig. 4A). In patients with exon 21 L858R mutation, using the percentage of mutant DNA above 4.77% as the cut-off value, a longer PFS was observed in high percentage of mutant DNA groups (12.2 months, 95% CI: 6.4–16.8) compared with low percentage mutant DNA groups (9.8 months, 95% CI: 5.7–12.3, \( P = 0.4454 \)) (Fig. 4B), although insignificant.

### 4. Discussion

In our study, we observed that the content of mutant EGFR DNA correlated with dCt detected by the Therascreen EGFR RGQ PCR kit (Qiagen) in lung cancer cells. In lung adenocarcinoma patients with common sensitizing EGFR mutations, the content of mutant DNA in lung cancer tissue samples correlated with the treatment response to EGFR-TKI. A higher percentage of mutant EGFR DNA was associated with a longer PFS after EGFR-TKI therapy. In addition, patients with exon 19 deletion mutations showed response to EGFR-TKI in lower contents of mutant EGFR DNA.

The Therascreen EGFR RGQ PCR kit assay is based on allele-specific amplification of mutant EGFR sequences using real-time polymerase chain reaction (PCR). It has been approved in the United States, Europe, and Asian countries with the purpose to detect of EGFR mutations with high sensitivity and specificity.\(^{[17]}\) PCR-based methods have been used in the determination of allele frequency in DNA samples.\(^{[18]}\) Thus, the Therascreen EGFR RGQ PCR kit assay was used in our study to determine the content of mutant EGFR DNA in lung cancer cells and tissues. From the literature review, we developed a method to quantify the content of mutant EGFR DNA using the Therascreen EGFR RGQ PCR kit assay for the first time.

Of EGFR-TKI nonresponders, 20% to 30% were noted in NSCLC patients with EGFR mutations receiving EGR-TKIs therapy.\(^{[9,10,19]}\) In EGFR-TKI nonresponders, inferior PFS and

### Table 2

| Variable        | TKIs responder/ nonresponder | aOR | 95% CI       | \( P \)  value |
|-----------------|------------------------------|-----|--------------|--------------|
| Gender          |                              |     |              |              |
| Male            | 30/7                         | 0.67| 0.14–3.11    | 0.6101       |
| Female          | 31/9                         | 1.00|              | 1.00         |
| Smoking         |                              |     |              |              |
| Yes             | 7/2                          | 0.43| 0.05–4.01    | 0.4593       |
| No              | 54/14                        | 1.00|              | 1.00         |
| Age, y          |                              |     |              |              |
| ≥65             | 35/12                        | 0.33| 0.06–1.66    | 0.1767       |
| <65             | 26/4                         | 1.00|              | 1.00         |
| Mutation        |                              |     |              |              |
| Exon 19         | 30/4                         | 3.21| 0.78–13.29   | 0.1075       |
| Exon 21         | 31/12                        | 1.00|              | 1.00         |
| DNA content     |                              |     |              |              |
| High            | 50/5                         | 13.07| 3.23–52.11  | 0.0003\(^*\) |
| Low             | 11/11                        | 1.00|              | 1.00         |

*aOR = adjusted odds ratio for all variables in the model, CI = confidence interval, DNA = deoxyribonucleic acid, EGFR-TKI = epidermal growth factor tyrosine kinase inhibitor.

\(^*\) \( P < 0.05 \).
OS were observed compared with EGFR-TKI responders. A recent study reported that the median OS was 21 months (95% CI: 26.1–30.4) in responders compared with 8 months (95% CI: 8.7–15.8) in nonresponders. Since an inferior prognosis was noted in this group of patients, close monitoring for treatment response after the initiation of EGFR-TKI treatment is advocated with the purpose to identify EGFR-TKI nonresponders for early treatment adjustment. Our study results may help to further identify the EGFR-TKI nonresponders before the initiation of EGFR-TKI therapy.

Primary resistance to EGFR-TKI of lung cancer cells is related to EGFR-TKI nonresponders. Primary EGFR-TKI resistance has been reported to be related to v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, phosphoinositide-3-kinase catalytic alpha (PIK3CA) mutation, de novo proto-oncogene MET amplification, Bim deletion polymorphism, phosphatase and tensin homolog (PTEN) loss, and de novo T790M mutation of the EGFR gene. Our study may provide another evidence that low content of mutant EGFR DNA in lung cancer tissues may cause primary resistance to EGFR-TKI in NSCLC patients with exon 21 L858R mutation. However, further study to elucidate the differences in mechanisms related to sensitivity to EGFR-TKI between L858R and exon 19 deletion mutations is still warranted.

A high content of mutant EGFR DNA is associated with increased response to EGFR-TKI therapy and PFS in our study. Increased copy number of the EGFR gene has been reported to be associated with increased response to EGFR-TKI therapy, PFS and OS. Copy number gain of the EGFR gene is associated with EGFR mutations in lung cancer cells and tissues. As the result, increased copy number of the EGFR gene may cause increased mutant EGFR DNA contents in EGFR mutation lung cancer tissues in our study. However, the association of the EGFR gene copy number and the content of mutant EGFR DNA in EGFR mutation lung cancer tissues still need further study.

In our study, exon 19 deletion mutations also showed favorable outcomes and responses to EGFR-TKI than L858R mutation in lower contents of mutant EGFR DNA. In previous studies, exon 19 deletion mutations have been reported to be associated with better outcomes than L858R mutations in patients with EGFR-TKI. Our study further showed that exon 19 deletions and L858R mutations are 2 distinct groups of
patients, and different clinical treatment strategy may be considered in the future.

In summary, our results showed that the content of mutant EGFR DNA is associated with the clinical response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations, especially in patients with exon 19 deletion mutations. The content of mutant EGFR DNA could be used as an indicator to predict response to EGFR-TKI therapy. Our results also add another mechanism that low content of mutant EGFR DNA may cause the primary resistance of EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations.

References

[1] Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(suppl 4):31–9.
[2] Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
[3] Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
[4] Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195–203.
[5] Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:527–62.
[6] Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007;2:430–9.
[7] Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles “heal” of lung cancers? Trends Mol Med 2004;10:481–6.
[8] Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
[9] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:375–82.
[10] Wu YL, Zhong WZ, Li LY, et al. Afatinib versus cisplatin plus gemcitabine for frontline treatment of Asian patients with advanced non-small-cell lung cancer harboring EGFR mutations (LU-16): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–22.
[11] Rekhtman N, Leighl NB, Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer association for molecular pathology guideline. J Oncol Pract 2015;11:135–6.
[12] Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet 2012;379:178–85.
[13] Taniguchi K, Okami J, Kodama K, et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99:928–35.
[14] Bai H, Wang Z, Wang Y, et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS ONE 2015;10:e014170.
[15] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
[16] Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163–7.
[17] Veller A, Le Loupp AG, Denis MG. Efficiency of the Therascreen(R) RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clin Chim Acta 2014;429:8–11.
[18] Wilkening S, Hemminki K, Thruman RK, et al. Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. BioTechniques 2003;39:853–8.
[19] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
[20] Kim GW, Song JS, Choi CM, et al. Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer 2015;88:139–46.
[21] Takeda M, Okamoto I, Fujita Y, et al. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol 2010;5:399–406.
[22] Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:707–15.
[23] Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298–304.
[24] Lee JY, Ku BM, Lim SH, et al. The BIM deletion polymorphism and its clinical implication in patients with EGFR-Mutant non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors. J Thorac Oncol 2015;10:903–9.
[25] Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256–61.
[26] Lee Y, Lee GK, Hwang JA, et al. Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. Clin Lung Cancer 2015;16:46–50.
[27] Chiu CH, Ho HL, Doong H, et al. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget 2015;6:9407–17.
[28] Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829–37.
[29] Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643–55.
[30] Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009;4:e7464.
[31] Liang Z, Zhang J, Zeng X, et al. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010;10:376.
[32] Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:833–44.
[33] Rossell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–67.